The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Targeted Delivery of CRISPR/Cas9‐Mediated Cancer Gene Therapy via Liposome‐Templated Hydrogel Nanoparticles
Open accessAbstract
Due to its simplicity, versatility, and high efficiency, the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 technology has emerged as one of the most promising approaches for treatment of a variety of genetic diseases, including human cancers. However, further translation of CRISPR/Cas9 for cancer gene therapy requires development of safe approaches for efficient, highly specific delivery of both Cas9 and single guide RNA to tumors. Here, novel core-shell nanostructure, liposome-templated hydrogel nanoparticles (LHNPs) that are optimized for efficient codelivery of Cas9 protein and nucleic acids is reported. It is demonstrated that, when coupled with the minicircle DNA technology, LHNPs deliver CRISPR/Cas9 with efficiency greater than commercial agent Lipofectamine 2000 in cell culture and can be engineered for targeted inhibition of genes in tumors, including tumors the brain. When CRISPR/Cas9 targeting a model therapeutic gene, polo-like kinase 1 (PLK1), is delivered, LHNPs effectively inhibit tumor growth and improve tumor-bearing mouse survival. The results suggest LHNPs as versatile CRISPR/Cas9-delivery tool that can be adapted for experimentally studying the biology of cancer as well as for clinically translating cancer gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After loading with CRISPR/Cas9 targeting polo-like kinase 1 (plk1) gene, LHNPs effectively inhibited U87MG tumor growth [119].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
Self-citationTissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Girard, O. M., Hanahan, D., Mattrey, R. F., & Ruoslahti, E. I. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.013 · Cited by 1,140
Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing
Tsai, S. Q., Wyvekens, N., Khayter, C., Foden, J. A., Thapar, V., Reyon, D., Goodwin, M. J., Aryee, M. J., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2908 · Cited by 952
CRISPR-mediated direct mutation of cancer genes in the mouse liver
Xue, W., Chen, S., Yin, H., Tammela, T., Papagiannakopoulos, T., Joshi, N. S., Cai, W., Yang, G., Bronson, R., Crowley, D. G., et al. (2014) · Nature · doi:10.1038/nature13589 · Cited by 776
In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9
Swiech, L., Heidenreich, M., Banerjee, A., Habib, N., Li, Y., Trombetta, J., Sur, M., & Zhang, F. (2015) · Nature Biotechnology · doi:10.1038/nbt.3055 · Cited by 772
Cheng, A. W., Wang, H., Yang, H., Shi, L., Yarden Katz, A., Theunissen, T. W., Rangarajan, S., Shivalila, C., Dadon, D. B., & Jaenisch, R. (2013) · Cell Research · doi:10.1038/cr.2013.122 · Cited by 768
Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection
Liang, X., Potter, J., Kumar, S., Zou, Y., Quintanilla, R., Sridharan, M., Carte, J., Chen, W., Roark, N., Ranganathan, S., et al. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.04.024 · Cited by 733
The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses
Deeken, J. F., & Löscher, W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2854 · Cited by 724
Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA
Ramakrishna, S., Kwaku Dad, A.-B., Beloor, J., Gopalappa, R., Lee, S.-K., & Kim, H. (2014) · Genome Research · doi:10.1101/gr.171264.113 · Cited by 655
Self‐assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506030 · Cited by 629
Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles
Wang, M., Zuris, J. A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Pouli, D., Wu, Q., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520244113 · Cited by 624
Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing
Mout, R., Ray, M., Yesilbag Tonga, G., Lee, Y.-W., Tay, T., Sasaki, K., & Rotello, V. M. (2017) · ACS Nano · doi:10.1021/acsnano.6b07600 · Cited by 579
Miller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., Zhu, H., & Siegwart, D. J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610209 · Cited by 540
Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery
Zhou, J., Liu, J., Cheng, C. J., Patel, T., Weller, C. E., Piepmeier, J. M., Jiang, Z., & Saltzman, W. M. (2011) · Nature Materials · doi:10.1038/nmat3187 · Cited by 391
Self-citationA robust system for production of minicircle DNA vectors
Kay, M. A., He, C.-Y., & Chen, Z.-Y. (2010) · Nature Biotechnology · doi:10.1038/nbt.1708 · Cited by 329
Self-citationPorteous, D. J., DORIN, J., McLachlan, G., Davidson‐Smith, H., Davidson, H., Stevenson, B., Carothers, A. D., Wallace, W., Mora-Lee, S., Hoenes, C., et al. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300390 · Cited by 323
A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo
Jiang, C., Mei, M., Li, B., Zhu, X., Zu, W., Tian, Y., Wang, Q., Guo, Y., Dong, Y., & Tan, X. (2017) · Cell Research · doi:10.1038/cr.2017.16 · Cited by 295
Xiang, S., Kato, M., Wu, L. C., Lin, Y., Ding, M., Zhang, Y., Yu, Y., & McKnight, S. L. (2015) · Cell · doi:10.1016/j.cell.2015.10.040 · Cited by 291
Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling
Zuckermann, M., Hovestadt, V., Knobbe-Thomsen, C. B., Zapatka, M., Northcott, P. A., Schramm, K., Belic, J., Jones, D. T. W., Tschida, B., Moriarity, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8391 · Cited by 283
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma
Zhou, J., Patel, T., Sirianni, R. W., Strohbehn, G. W., Zheng, M., Duong, N. T., Schafbauer, T., Huttner, A. J., Huang, Y. H., Carson, R. E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304504110 · Cited by 277
Self-citationAdenosine Receptor Signaling Modulates Permeability of the Blood–Brain Barrier
Carman, A. J., Mills, J. H., Krenz, A., Kim, D.-G., & Bynoe, M. S. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3337-11.2011 · Cited by 276
CRISPR/Cas9‐mediated genome engineering: An adeno‐associated viral (AAV) vector toolbox
Senís, E., Fatouros, C., Große, S., Wiedtke, E., Niopek, D., Mueller, A., Börner, K., & Grimm, D. (2014) · Biotechnology Journal · doi:10.1002/biot.201400046 · Cited by 268
Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice
Li, L., Song, L., Liu, X., Yang, X., Li, X., He, T., Wang, N., Yang, S., Yu, C., Yin, T., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b04261 · Cited by 244
Non-viral is superior to viral gene delivery
Li, S.-D., & Huang, L. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.09.004 · Cited by 225
Lu, C., Stewart, D. J., Lee, J. J., Ji, L., Ramesh, R., Jayachandran, G., Nunez, M. I., Wistuba, I. I., Erasmus, J. J., Hicks, M. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034833 · Cited by 184
Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors
Zhou, J., Patel, T., Fu, M. C., Bertram, J. P., & Saltzman, W. M. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.061 · Cited by 176
Self-citationKouranova, E. V., Forbes, K. P., Zhao, G., Warren, J., Bartels, A., Wu, Y., & Cui, X. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.009 · Cited by 151
Salomone, F., Cardarelli, F., Luca, M. D., Boccardi, C., Nifosı̀, R., Bardi, G., Bari, L. D., Serresi, M., & Beltram, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.019 · Cited by 147
Novel Delivery Strategies for Glioblastoma
Zhou, J., Atsina, K., Himes, B. T., Strohbehn, G. W., & Saltzman, W. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318244d8ae · Cited by 128
Self-citationHan, L., Kong, D. K., Zheng, M.-Q., Murikinati, S., Ma, C., Yuan, P., Li, L., Tian, D., Cai, Q., Ye, C., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b07573 · Cited by 122
Self-citationEngineering Delivery Vehicles for Genome Editing
Nelson, C. E., & Gersbach, C. A. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-034711 · Cited by 120
Keeney, M., Ong, S., Padilla-Lopez, A., Yao, Z., Goodman, S. B., Wu, J. C., & Yang, F. (2013) · ACS Nano · doi:10.1021/nn402657d · Cited by 87
Gwiazda, K., Grier, A. E., Sahni, J., Burleigh, S. M., Martin, U., Yang, J., Popp, N. A., Krutein, M. C., Khan, I., Jacoby, K., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.105 · Cited by 35
Surveying the Delivery Methods of CRISPR/Cas9 for ex vivo Mammalian Cell Engineering
Kelton, W., Pesch, T., Matile, S., & Reddy, S. T. (2016) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2016.439 · Cited by 13
Genetic Characteristics of Glioblastoma: Clinical Implications of Heterogeneity
Tu, Y., & Li, Q. (2015) · Cancer translational medicine · doi:10.4103/2395-3977.168573 · Cited by 7
Research works printed but not linked: 2
- 10.1126/science.1225829 · DOI · Paper page
- 10.1038/nmeth.3047 · DOI · Paper page
Cited by
Sorted by citations
CRISPR technology: A decade of genome editing is only the beginning
Wang, J. Y., & Doudna, J. A. (2023) · Science · doi:10.1126/science.add8643 · Cited by 1,105
Lu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 762
Recent advancements in liposome technology
Filipczak, N., Pan, J., Yalamarty, S. S. K., & Torchilin, V. P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.022 · Cited by 611
Hersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
Base editing: advances and therapeutic opportunities
Porto, E. M., Komor, A. C., Slaymaker, I. M., & Yeo, G. W.-M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0084-6 · Cited by 499
Metadata
- Authors
- Chen, Z., Liu, F., Chen, Y., Liu, J., Wang, X., Chen, A. T., Deng, G., Zhang, H., Liu, J., Hong, Z., & Zhou, J.
- Affiliations
- Nankai University (CN)
- Yale University (US)
- Corresponding author
- Hong, Zhangyong
- Zhou, Jiangbing
- ORCID
- Venue
- Advanced Functional Materials
- Publisher
- Wiley
- Published
- 2017-10-16
- Volume
- 27
- Issue
- 46
- ISSN
- 1616-301X (ISSN-L)
- 1616-3028
- PMC
- PMC5939593
- OpenAlex
- W2766680713
- Cited by
- 297
- References
- 41
- Citations by year
- 2026: 11 · 2025: 44 · 2024: 26 · 2023: 39 · 2022: 60 · 2021: 37 · 2020: 39 · 2019: 24 · 2018: 16
- FWCI
- 8.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Advanced Functional Materials (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (NS095817, NS095147)
- American Brain Tumor Association
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- CRISPR/Cas9, cancer gene therapy, core-shell nanoparticles, nucleic acid delivery, DNA minicircles, single guide RNA, targeted tumor delivery, brain tumors, PLK1, tumor growth inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
